Generic placeholder image

Current Neurovascular Research

Editor-in-Chief

ISSN (Print): 1567-2026
ISSN (Online): 1875-5739

Research Article

Association of Posture Instability with Dopamine Drop of Nigrostriatal System and Hypometabolism of Cerebral Cortex in Parkinson’s Disease

Author(s): Hongyan Wang, Hong-Yu Li, Xiuhai Guo and Yongtao Zhou*

Volume 18, Issue 2, 2021

Published on: 03 June, 2021

Page: [244 - 253] Pages: 10

DOI: 10.2174/1567202618666210603124814

Price: $65

conference banner
Abstract

Background: Posture Instability (PI) is known to be a severe complication in Parkinson’s Disease (PD), and its mechanism remains poorly understood. Our study aims to explore the changes of brain network in PI of PD, and further investigate the role of peripheral inflammation on activities of different brain regions in PD with PI.

Methods: 167 individuals were recruited, including 36 PD cases with PI and 131 ones without PI. We carefully assessed the status of motor and cognitive function, measured serum inflammatory factors, and detected the dopaminergic pathways and the metabolism of different brain regions by Positron Emission Tomography (PET). Data analysis was conducted by variance, univariate analysis, chi-square analysis, logistic regression, and partial correlation.

Results: No difference was found for age or onset age between the two groups (P>0.05). Female patients were susceptible to posture impairment and had a 2.14-fold risk for PI compared with male patients in PD (P<0.05). Patients with PI had more severe impairment of motor and cognitive function for a longer duration than those without PI (P<0.05). The mean uptake ratios of presynaptic vesicular monoamine transporter (VMAT2), which were detected in the caudate nucleus and putamen, were lower in PI group than those without PI (P<0.05). There were lower activities of the midbrain, caudate nucleus, and anterior medial temporal cortex in PI group than those in the non-PI group (P<0.05). Although serum concentrations of immunoglobulins (IgG, IgM, and IgA) and complements (C3, C4) were higher in the PI group than those in the non-PI group, only serum IgM concentration had a significant difference between the two groups (P<0.05). We further explored significant inverse correlations of IgG, IgM, IgA, and C4 with activities of some cerebral cortex in PI of PD (P<0.05).

Conclusion: Female patients were susceptible to posture instability and had a 2.14-fold risk for PI of PD. Patients with PI had more severe impairments of motor and cognitive function for a longer duration than those without PI. PI was associated with a dopamine drop of the nigrostriatal system and lower activities of the limbic cortex in PD. Peripheral inflammation may be involved in degeneration of the cerebral cortex in PD combined with PI.

Keywords: Parkinson disease, posture instability, dopamine, inflammation factors, limbic cortex, PET-CT.

[1]
Beydoun HA, Beydoun MA, Mishra NK, Rostant OS, Zonderman AB, Eid SM. Comorbid Parkinson’s disease, falls and fractures in the 2010 National Emergency Department sample. Parkinsonism Relat Disord 2017; 35: 30-5.
[http://dx.doi.org/10.1016/j.parkreldis.2016.11.005] [PMID: 27887896]
[2]
Mühlenfeld N, Söhling N, Marzi I, et al. Fractures in parkinson's disease: Injury patterns, hospitalization, and therapeutic aspects. Eur J Trauma Emerg Surg 2021; 47: 573-80.
[http://dx.doi.org/10.1007/s00068-019-01240-z]
[3]
François C, Biaggioni I, Shibao C, et al. Fall-related healthcare use and costs in neurogenic orthostatic hypotension with Parkinson’s disease. J Med Econ 2017; 20(5): 525-32.
[http://dx.doi.org/10.1080/13696998.2017.1284668] [PMID: 28125950]
[4]
Chang FC, Tsui DS, Mahant N, et al. 24 h Levodopa-carbidopa intestinal gel may reduce falls and “unresponsive” freezing of gait in Parkinson’s disease. Parkinsonism Relat Disord 2015; 21(3): 317-20.
[http://dx.doi.org/10.1016/j.parkreldis.2014.12.019] [PMID: 25578290]
[5]
Johnson L, Rodrigues J, Teo W-P, et al. Interactive effects of GPI stimulation and levodopa on postural control in Parkinson’s disease. Gait Posture 2015; 41(4): 929-34.
[http://dx.doi.org/10.1016/j.gaitpost.2015.03.346] [PMID: 25861706]
[6]
Wilson J, Alcock L, Yarnall AJ, et al. Gait progression over 6 years in parkinson’s disease: Effects of age, medication, and pathology. Front Aging Neurosci 2020; 12: 577435.
[http://dx.doi.org/10.3389/fnagi.2020.577435] [PMID: 33192470]
[7]
Smulders K, Dale ML, Carlson-Kuhta P, Nutt JG, Horak FB. Pharmacological treatment in Parkinson’s disease: Effects on gait. Parkinsonism Relat Disord 2016; 31: 3-13.
[http://dx.doi.org/10.1016/j.parkreldis.2016.07.006] [PMID: 27461783]
[8]
Curtze C, Nutt JG, Carlson-Kuhta P, Mancini M, Horak FB. Levodopa is a double-edged sword for balance and gait in people with Parkinson’s disease. Mov Disord 2015; 30(10): 1361-70.
[http://dx.doi.org/10.1002/mds.26269] [PMID: 26095928]
[9]
Curtze C, Nutt JG, Carlson-Kuhta P, Mancini M, Horak FB. Objective gait and balance impairments relate to balance confidence and perceived mobility in people with parkinson disease. Phys Ther 2016; 96(11): 1734-43.
[http://dx.doi.org/10.2522/ptj.20150662] [PMID: 27149959]
[10]
Bohnen NI, Müller ML, Koeppe RA, et al. History of falls in Parkinson disease is associated with reduced cholinergic activity. Neurology 2009; 73(20): 1670-6.
[http://dx.doi.org/10.1212/WNL.0b013e3181c1ded6] [PMID: 19917989]
[11]
Takakusaki K. Functional neuroanatomy for posture and gait control. J Mov Disord 2017; 10(1): 1-17.
[http://dx.doi.org/10.14802/jmd.16062] [PMID: 28122432]
[12]
de Lima-Pardini AC, Coelho DB, Nucci MP, et al. Brain networks associated with anticipatory postural adjustments in Parkinson’s disease patients with freezing of gait. Neuroimage Clin 2020; 28: 102461.
[http://dx.doi.org/10.1016/j.nicl.2020.102461] [PMID: 33395957]
[13]
Marquez JS, Hasan SMS, Siddiquee MR, et al. Neural correlates of freezing of gait in parkinson’s disease: An electrophysiology mini-review. Front Neurol 2020; 11: 571086.
[http://dx.doi.org/10.3389/fneur.2020.571086] [PMID: 33240199]
[14]
Donato R, Pavan A, Campana G. Investigating the interaction between form and motion processing: A review of basic research and clinical evidence. Front Psychol 2020; 11: 566848.
[http://dx.doi.org/10.3389/fpsyg.2020.566848] [PMID: 33192845]
[15]
Parr T, Sajid N, Da Costa L, Mirza MB, Friston KJ. Generative models for active vision. Front Neurorobot 2021; 15: 651432.
[http://dx.doi.org/10.3389/fnbot.2021.651432] [PMID: 33927605]
[16]
Mattis PJ, Niethammer M, Sako W, et al. Distinct brain networks underlie cognitive dysfunction in Parkinson and Alzheimer diseases. Neurology 2016; 87(18): 1925-33.
[http://dx.doi.org/10.1212/WNL.0000000000003285] [PMID: 27708130]
[17]
Niethammer M, Tang CC, Ma Y, et al. Parkinson’s disease cognitive network correlates with caudate dopamine. Neuroimage 2013; 78: 204-9.
[http://dx.doi.org/10.1016/j.neuroimage.2013.03.070] [PMID: 23578575]
[18]
Mattis PJ, Tang CC, Ma Y, Dhawan V, Eidelberg D. Network correlates of the cognitive response to levodopa in Parkinson disease. Neurology 2011; 77(9): 858-65.
[http://dx.doi.org/10.1212/WNL.0b013e31822c6224] [PMID: 21849641]
[19]
Bohnen NI, Albin RL. The cholinergic system and Parkinson disease. Behav Brain Res 2011; 221(2): 564-73.
[http://dx.doi.org/10.1016/j.bbr.2009.12.048] [PMID: 20060022]
[20]
Avila C, Kucinski A, Sarter M. Complex movement control in a rat model of parkinsonian falls: Bidirectional control by striatal cholinergic interneurons. J Neurosci 2020; 40(31): 6049-67.
[http://dx.doi.org/10.1523/JNEUROSCI.0220-20.2020] [PMID: 32554512]
[21]
Pak K, Shin HK, Kim EJ, et al. Weight loss is associated with rapid striatal dopaminergic degeneration in Parkinson’s disease. Parkinsonism Relat Disord 2018; 51: 67-72.
[http://dx.doi.org/10.1016/j.parkreldis.2018.02.044] [PMID: 29510907]
[22]
Zhou Y, Zhao J, Hou Y, Su Y, Chan P, Wang Y. Dopaminergic pathway and primary visual cortex are involved in the freezing of gait in Parkinson’s disease: A PET-CT study. Neuropsychiatr Dis Treat 2019; 15: 1905-14.
[http://dx.doi.org/10.2147/NDT.S197879] [PMID: 31410003]
[23]
Wei H, Zhou Y, Zhao J, Zhan L. Risk factors and metabolism of different brain regions by positron emission tomography in parkinson disease with disabling dyskinesia. Curr Neurovasc Res 2019; 16(4): 310-20.
[http://dx.doi.org/10.2174/1567202616666191009102112] [PMID: 31622205]
[24]
Xu SS, Alexander PK, Lie Y, et al. Diagnostic accuracy of imaging brain vesicular monoamine transporter type 2 (VMAT2) in clinically uncertain parkinsonian syndrome (CUPS): A 3-year follow-up study in community patients. BMJ Open 2018; 8(11): e025533.
[http://dx.doi.org/10.1136/bmjopen-2018-025533] [PMID: 30446576]
[25]
Hoehn MM, Yahr MD. Parkinsonism: Onset, progression, and mortality. 1967. Neurology 2006; 15(3): 307-12.
[26]
Fahn S, Elton RL. Unified Parkinson’s disease rating scale.Recent developments in Parkinson’s disease. Florham Park: Macmillan healthcare information 1987; pp. 153-63.
[27]
Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord 2010; 25(15): 2649-53.
[http://dx.doi.org/10.1002/mds.23429] [PMID: 21069833]
[28]
Zhou YT, Zhang ZX, Chan P, et al. Genetic association between low-density lipoprotein receptor-related protein gene polymorphisms and Alzheimer’s disease in Chinese Han population. Neurosci Lett 2008; 444(1): 109-11.
[http://dx.doi.org/10.1016/j.neulet.2008.07.093] [PMID: 18706476]
[29]
Doty RL, Shaman P, Dann M. Development of the university of pennsylvania smell identification test: A standardized microencapsulated test of olfactory function. Physiol Behav 1984; 32(3): 489-502.
[http://dx.doi.org/10.1016/0031-9384(84)90269-5] [PMID: 6463130]
[30]
Zhou Y, Su Y, Xu W, Wang W, Yao S. Constipation increases disability and decreases dopamine levels in the nigrostriatal system through gastric inflammatory factors in parkinson’s disease. Curr Neurovasc Res 2019; 16(3): 241-9.
[http://dx.doi.org/10.2174/1567202616666190618170103] [PMID: 31258082]
[31]
Sun C, Yu W, Zhao Z, et al. Peripheral humoral immune response is associated with the non-motor symptoms of parkinson’s disease. Front Neurosci 2019; 13: 1057.
[http://dx.doi.org/10.3389/fnins.2019.01057] [PMID: 31649497]
[32]
An SJ, Lee SH, Lee SY, Kwon JW, Lee SJ, Kim YJ. Femur Fractures in parkinsonism: Analysis of a national sample cohort in South Korea. J Clin Neurol 2017; 13(4): 380-6.
[http://dx.doi.org/10.3988/jcn.2017.13.4.380] [PMID: 29057630]
[33]
Keshishian A, Boytsov N, Burge R, et al. Examining the treatment gap and risk of subsequent fractures among females with a fragility fracture in the US Medicare population. Osteoporos Int 2017; 28(8): 2485-94.
[http://dx.doi.org/10.1007/s00198-017-4072-6] [PMID: 28536737]
[34]
Almada M, Brochado P, Portela D, Midão L, Costa E. Prevalence of falls and associated factors among community-dwelling older adults: A cross-sectional study. J Frailty Aging 2021; 10(1): 10-6.
[PMID: 33331616]
[35]
Kiesmann M, Sauleau E, Perisse J, et al. Parkinsonian gait in elderly people: Significance of the threshold value of two and more falls per year. Rev Neurol 2020; S0035-3787(20): 30662-5.
[36]
Harro CC, Kelch A, Hargis C, DeWitt A. Comparing balance performance on force platform measures in individuals with parkinson’s disease and healthy adults. Parkinsons Dis 2018; 2018: 6142579.
[http://dx.doi.org/10.1155/2018/6142579] [PMID: 30687494]
[37]
Peterson DS, Horak FB. The effect of levodopa on improvements in protective stepping in people with parkinson’s disease. Neurorehabil Neural Repair 2016; 30(10): 931-40.
[http://dx.doi.org/10.1177/1545968316648669] [PMID: 27162165]
[38]
Çekok K, Kahraman T, Duran G, et al. Timed up and go test with a cognitive task: Correlations with neuropsychological measures in people with parkinson’s disease. Cureus 2020; 12(9): e10604.
[PMID: 33123423]
[39]
Pantall A, Suresparan P, Kapa L, et al. Postural dynamics are associated with cognitive decline in parkinson’s disease. Front Neurol 2018; 9: 1044.
[http://dx.doi.org/10.3389/fneur.2018.01044] [PMID: 30568629]
[40]
Unger J, Chan K, Lee JW, et al. The effect of perturbation-based balance training and conventional intensive balance training on reactive stepping ability in individuals with incomplete spinal cord injury or disease: A randomized clinical trial. Front Neurol 2021; 12: 620367.
[http://dx.doi.org/10.3389/fneur.2021.620367] [PMID: 33603710]
[41]
Peterson DS, King LA, Cohen RG, Horak FB. Cognitive contributions to freezing of gait in parkinson disease: Implications for physical rehabilitation. Phys Ther 2016; 96(5): 659-70.
[http://dx.doi.org/10.2522/ptj.20140603] [PMID: 26381808]
[42]
Paul SS, Sherrington C, Canning CG, Fung VS, Close JC, Lord SR. The relative contribution of physical and cognitive fall risk factors in people with Parkinson’s disease: A large prospective cohort study. Neurorehabil Neural Repair 2014; 28(3): 282-90.
[http://dx.doi.org/10.1177/1545968313508470] [PMID: 24243915]
[43]
Hsiao IT, Weng YH, Hsieh CJ, et al. Correlation of Parkinson disease severity and 18F-DTBZ positron emission tomography. JAMA Neurol 2014; 71(6): 758-66.
[http://dx.doi.org/10.1001/jamaneurol.2014.290] [PMID: 24756323]
[44]
Takakusaki K, Habaguchi T, Ohtinata-Sugimoto J, Saitoh K, Sakamoto T. Basal ganglia efferents to the brainstem centers controlling postural muscle tone and locomotion: A new concept for understanding motor disorders in basal ganglia dysfunction. Neuroscience 2003; 119(1): 293-308.
[http://dx.doi.org/10.1016/S0306-4522(03)00095-2] [PMID: 12763089]
[45]
Nakajima M, Schmitt LI, Halassa MM. Prefrontal cortex regulates sensory filtering through a basal ganglia-to-thalamus pathway. Neuron 2019; 103(3): 445-58.
[http://dx.doi.org/10.1016/j.neuron.2019.05.026] [PMID: 31202541]
[46]
Schultz W. Reward functions of the basal ganglia. J Neural Transm (Vienna) 2016; 123(7): 679-93.
[http://dx.doi.org/10.1007/s00702-016-1510-0] [PMID: 26838982]
[47]
Herrero MT, Barcia C, Navarro JM. Functional anatomy of thalamus and basal ganglia. Childs Nerv Syst 2002; 18(8): 386-404.
[http://dx.doi.org/10.1007/s00381-002-0604-1] [PMID: 12192499]
[48]
Nambu A. Seven problems on the basal ganglia. Curr Opin Neurobiol 2008; 18(6): 595-604.
[http://dx.doi.org/10.1016/j.conb.2008.11.001] [PMID: 19081243]
[49]
Hoehn MM, Yahr MD. Parkinsonism: Onset, progression and mortality. Neurology 1967; 17(5): 427-42.
[http://dx.doi.org/10.1212/WNL.17.5.427] [PMID: 6067254]
[50]
Kim R, Lee J, Kim Y, et al. Presynaptic striatal dopaminergic depletion predicts the later development of freezing of gait in de novo Parkinson’s disease: An analysis of the PPMI cohort. Parkinsonism Relat Disord 2018; 51: 49-54.
[http://dx.doi.org/10.1016/j.parkreldis.2018.02.047] [PMID: 29523394]
[51]
Sun X, Liu F, Liu Q, et al. Quantitative research of 11c-cft and 18f-fdg pet in parkinson’s disease: A pilot study with neuroq software. Front Neurosci 2019; 13: 299.
[http://dx.doi.org/10.3389/fnins.2019.00299] [PMID: 31024233]
[52]
Kravitz DJ, Saleem KS, Baker CI, Mishkin M. A new neural framework for visuospatial processing. Nat Rev Neurosci 2011; 12(4): 217-30.
[http://dx.doi.org/10.1038/nrn3008] [PMID: 21415848]
[53]
Georgopoulos AP, Grillner S. Visuomotor coordination in reaching and locomotion. Science 1989; 245(4923): 1209-10.
[http://dx.doi.org/10.1126/science.2675307] [PMID: 2675307]
[54]
Tankus A, Fried I. Visuomotor coordination and motor representation by human temporal lobe neurons. J Cogn Neurosci 2012; 24(3): 600-10.
[http://dx.doi.org/10.1162/jocn_a_00160] [PMID: 22066588]
[55]
Al-Bachari S, Vidyasagar R, Emsley HC, Parkes LM. Structural and physiological neurovascular changes in idiopathic Parkinson’s disease and its clinical phenotypes. J Cereb Blood Flow Metab 2017; 37(10): 3409-21.
[http://dx.doi.org/10.1177/0271678X16688919] [PMID: 28112022]
[56]
Al-Bachari S, Naish JH, Parker GJM, Emsley HCA, Parkes LM. Blood-brain barrier leakage is increased in parkinson’s disease. Front Physiol 2020; 11: 593026.
[http://dx.doi.org/10.3389/fphys.2020.593026] [PMID: 33414722]
[57]
Fuzzati-Armentero MT, Cerri S, Blandini F. Peripheral-central neuroimmune crosstalk in parkinson’s disease: What do patients and animal models tell us? Front Neurol 2019; 10: 232.
[http://dx.doi.org/10.3389/fneur.2019.00232] [PMID: 30941089]
[58]
Olajide OJ, Suvanto ME, Chapman CA. Molecular mechanisms of neurodegeneration in the entorhinal cortex that underlie its selective vulnerability during the pathogenesis of Alzheimer’s disease. Biol Open 2021; 10(1): bio056796.
[http://dx.doi.org/10.1242/bio.056796] [PMID: 33495355]
[59]
Hirsch EC, Vyas S, Hunot S. Neuroinflammation in Parkinson’s disease. Parkinsonism Relat Disord 2012; 18(Suppl. 1): S210-2.
[http://dx.doi.org/10.1016/S1353-8020(11)70065-7] [PMID: 22166438]
[60]
Franco R, Reyes-Resina I, Navarro G. Dopamine in health and disease: Much more than a neurotransmitter. Biomedicines 2021; 9(2): 109.
[http://dx.doi.org/10.3390/biomedicines9020109] [PMID: 33499192]
[61]
Wang Y, Hancock AM, Bradner J, et al. Complement 3 and factor h in human cerebrospinal fluid. Am J Pathol 2011; 78(4): 1509-16.
[62]
Orr CF, Rowe DB, Mizuno Y, Mori H, Halliday GM. A possible role for humoral immunity in the pathogenesis of Parkinson’s disease. Brain 2005; 128(Pt 11): 2665-74.
[http://dx.doi.org/10.1093/brain/awh625] [PMID: 16219675]
[63]
Süβ P, Lana AJ, Schlachetzki JCM. Chronic peripheral inflammation: A possible contributor to neurodegenerative diseases. Neural Regen Res 2021; 16(9): 1711-4.
[http://dx.doi.org/10.4103/1673-5374.306060] [PMID: 33510059]
[64]
Jain P, Chaney AM, Carlson ML, Jackson IM, Rao A, James ML. Neuroinflammation pet imaging: Current opinion and future directions. J Nucl Med 2020; 61(8): 1107-12.
[http://dx.doi.org/10.2967/jnumed.119.229443] [PMID: 32620705]
[65]
Foray C, Valtorta S, Barca C, et al. Imaging temozolomide-induced changes in the myeloid glioma microenvironment. Theranostics 2021; 11(5): 2020-33.
[http://dx.doi.org/10.7150/thno.47269] [PMID: 33500706]
[66]
Andersen MS, Bandres-Ciga S, Reynolds RH, et al. Heritability enrichment implicates microglia in Parkinson's disease pathogenesis. Ann Neurol 2021; 89(5): 942-51.
[PMID: 33502028]
[67]
Sandhu JK, Kulka M. Decoding mast cell-microglia communication in neurodegenerative diseases. Int J Mol Sci 2021; 22(3): 1093.
[http://dx.doi.org/10.3390/ijms22031093] [PMID: 33499208]
[68]
Öberg M, Fabrik I, Fabrikova D, Zehetner N, Härtlova A. The role of innate immunity and inflammation in Parkinson´s disease. Scand J Immunol 2021; 93(5): e13022.
[http://dx.doi.org/10.1111/sji.13022] [PMID: 33471378]
[69]
Wang N, Zhou Y, Zhao L, et al. Ferulic acid delayed amyloid β-induced pathological symptoms by autophagy pathway via a fasting-like effect in Caenorhabditis elegans. Food Chem Toxicol 2020; 146: 111808.
[http://dx.doi.org/10.1016/j.fct.2020.111808] [PMID: 33045309]
[70]
Forloni G, La Vitola P, Cerovic M, Balducci C. Inflammation and parkinson’s disease pathogenesis: Mechanisms and therapeutic insight. Prog Mol Biol Transl Sci 2021; 177: 175-202.
[http://dx.doi.org/10.1016/bs.pmbts.2020.11.001] [PMID: 33453941]
[71]
Hung AY, Schwarzschild MA. Approaches to disease modification for parkinson's disease: Clinical trials and lessons learned. Neurotherapeutics 2020; 17(4): 1393-405.

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy